NCT03927677

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

A Phase 1, Open-label, Fixed-sequence, 2-way Drug Interaction Study to Evaluate the Effect of Colchicine on the Pharmacokinetics of LC350189 and the Effect of LC350189 on the Pharmacokinetics of Colchicine in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: LG Chem · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the PK, PD, safety, and tolerability of LC350189 and colchicine when administered alone and in combination in healthy subjects.

Conditions

• Gout
• Hyperuricemia

Interventions

Type	Name	Description
DRUG	Xanthine Oxidase Inhibitor	LC350189 200mg qd

Timeline

• Start date: 2019-11-05
• Primary completion: 2019-11-26
• Completion: 2019-11-26
• First posted: 2019-04-25
• Last updated: 2020-06-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study